Skip to main content
Clinical Trials/NCT04823858
NCT04823858
Active, Not Recruiting
N/A

A Prospective Data Collection Study of Patients Treated with a Single-Level Lumbar Interbody Fusion Stabilized with Pedicle Screws

3Spine20 sites in 1 country176 target enrollmentMay 25, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Lumbar Spine Degeneration
Sponsor
3Spine
Enrollment
176
Locations
20
Primary Endpoint
Serious device-related adverse events (SDAE)
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

This study is designed to collect real world evidence (RWE) safety and efficacy data on patients who plan to undergo a single-level Transforaminal lumbar interbody fusion (TLIF) or Posterior lumbar interbody fusion (PLIF) instrumented with pedicle screws, using the framework of a prospective clinical study (with defined enrollment criteria and pre-specified research follow-up timepoints).

Detailed Description

A prospective, multi-center (up to 25), non-blinded study of patients who plan to undergo a single-level Transforaminal lumbar interbody fusion (TLIF) or Posterior lumbar interbody fusion (PLIF) stabilized with pedicle screws. Investigators will only select those patients who are planned for treatment with on-label use of FDA cleared TLIF/PLIF devices (cage and screw system). At least 200 subjects with a potential sample size re-estimation at completion. The subjects will return for follow-up at 6-weeks, 3-months, 6-months, and then annually for 5-years post surgery.

Registry
clinicaltrials.gov
Start Date
May 25, 2021
End Date
November 15, 2029
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
3Spine
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female, age 21-80 (inclusive) with at least 3 years of life expectancy;
  • Subject plans to undergo a one-level Open or Mini-Open TLIF or PLIF procedure (stabilized with pedicle screws) independent of this research protocol;
  • Subject is to be treated with on-label use of an FDA-cleared TLIF or PLIF cage(s) and pedicle screw system independent of this research protocol;
  • The subject has a primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis of the lumbar spine at a single level from L1/L2 to L5/S1 confirmed by subject history and radiographic imaging (CT, MRI, X-rays) with no more than a Grade 1 (\<25% translation) spondylolisthesis. Symptomatic lumbar degeneration that may be associated with a co-morbid condition such as:
  • Herniated nucleus pulposus;
  • Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule;
  • Facet joint degeneration/osteophyte formation;
  • Spondylosis (defined by the presence of osteophytes);
  • Disc degeneration and/or annular degeneration; and/or
  • Lumbar stenosis defined by spinal cord or nerve root compression;

Exclusion Criteria

  • More than one vertebral level requiring treatment;
  • Previous instrumented surgery (i.e.: anterior disc replacement, spinal fusion, interspinous device, etc.) at the index lumbar level or an adjacent level;
  • Degenerative or lytic spondylolisthesis greater than Grade 1 (\<25% translation);
  • Rotatory scoliosis at the level to be treated;
  • Congenital bony and/or spinal cord abnormalities at the level to be treated;
  • Subcaudal defect, disrupting the integrity of the pedicle;
  • Clinically compromised vertebral bodies at the involved level due to current or past trauma, e.g., by the radiographic appearance of the fracture callus, malunion or nonunion;
  • Disrupted anterior longitudinal ligament at the index level;
  • Overlying thoracolumbar kyphosis (greater than or equal to 15 degrees) within one level (includes target and adjacent level) of the level to be treated;
  • Back pain of unknown etiology without leg pain;

Outcomes

Primary Outcomes

Serious device-related adverse events (SDAE)

Time Frame: 24 months

Subject success will be determined with the absence of any serious device-related adverse events (SDAE)

Oswestry Disability Index (ODI) Score

Time Frame: 24 months compared to baseline

Improvement of at least 15 points in ODI score (out of 100). The ODI is a self-reported questionnaire that contains ten sections concerning intensity of pain, lifting, personal care, walking, sitting, sexual function, standing, social life, sleeping and traveling.

Secondary surgical intervention (SSI)

Time Frame: 24 months

Subject success will be determined with the absence of a secondary surgical intervention including revision, re-operation, removal, or supplemental fixation at the index level.

Neurological Status

Time Frame: 24 months compared to baseline

Absence of deterioration in neurological status compared to baseline examinations. Neurological examination will consist of a motor and sensory examination at each in person study visit conducted per physician standard of care.

Secondary Outcomes

  • VAS(24 months compared to baseline)
  • VAS - Back(24 months compared to baseline)
  • Visual Analog Score (VAS) - Worst Leg(24 months compared to baseline)
  • ODI(24 months compared to baseline)

Study Sites (20)

Loading locations...

Similar Trials